5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The impact of COVID-19 on households’ water use in Uganda

      1 , 2 , 1 , 3 , 2
      Water Supply
      IWA Publishing

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The unprecedented outbreak of COVID-19 necessitated the promotion of better hygiene practices to curb the spread of the virus. Better hygiene requires that households have a stable supply of water. However, little is known about the predictors of changes in water use in emergency situations such as COVID-19 in Uganda. This study uses data from a cross-sectional survey to examine the changes in the quantities of water used by 1,639 Ugandan households due to COVID-19. This article also explores the factors that are associated with changes in water use. The month March 2020 is used in this study as a cut-off because this is the month in which the government implemented a lockdown to curb the spread of the virus. Results indicate that most households had an increase in the quantity of water used after March 2020 when compared with the period before March 2020. Household characteristics that were associated with a change in the quantity of water used were age, sex, education, main occupation of household head, household size and region of residence. The results can be used to inform the prediction and demand modelling of household water use for improved water interventions for equitable water supply during emergencies.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: found

          World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

          An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Time-Inconsistent Preferences and Consumer Self-Control

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease

              As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7–10% and median time to intensive care admission is 9.5–10.5 days with mortality of around 1–2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.
                Bookmark

                Author and article information

                Journal
                Water Supply
                IWA Publishing
                1606-9749
                1607-0798
                August 01 2021
                February 12 2021
                August 01 2021
                February 12 2021
                : 21
                : 5
                : 2489-2504
                Affiliations
                [1 ]College of Engineering, Design Art and Technology, Department of Civil and Environmental Engineering, Makerere University, Kampala, Uganda
                [2 ]College of Business and Management Sciences, Department of Population Studies, Makerere University, Kampala, Uganda
                [3 ]College of Engineering, Design Art and Technology, Department of Construction Economics and Management, Makerere University, Kampala, Uganda
                Article
                10.2166/ws.2021.044
                ba3d711c-8b12-4f95-b794-7b688b351c8f
                © 2021

                http://creativecommons.org/licenses/by/4.0/

                History

                Comments

                Comment on this article